Europe High Content Screening Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2030 |
 Taille du marché (année de référence) |
|
 Taille du marché (année de prévision) |
Dollars américains 1,057,169.94 |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché européen du criblage à haut contenu, par type de produit (instruments, consommables, logiciels, services et accessoires), application (criblage primaire et secondaire, identification et validation de cibles, études de toxicité, profilage de composés et autres applications), technologie (microscopie, cytométrie de flux , immunohistochimie, échafaudage basé sur une matrice extracellulaire, ELISA, Western Blotting et autres), utilisateur final (sociétés pharmaceutiques et biotechnologiques, organismes de recherche sous contrat, laboratoires, instituts universitaires et gouvernementaux, autres), canal de distribution (appels d'offres directs, ventes au détail) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché européen de la diffusion de contenu à haut contenu
L'adoption croissante des HCS dans les activités de recherche telles que l'analyse cellulaire et la découverte de médicaments a accru la demande du marché. Les initiatives gouvernementales croissantes et le financement de la découverte de médicaments et des programmes de recherche connexes contribuent également à la croissance du marché. Les principaux acteurs du marché se concentrent sur divers lancements et approbations de services au cours de cette période cruciale. En outre, l'augmentation des progrès des techniques d'imagerie et de l'intelligence artificielle avec les systèmes HCS contribue également à la demande croissante de HCS.
Le marché devrait croître au cours de l'année de prévision en raison de l'augmentation du nombre d'acteurs sur le marché et de la disponibilité d'équipements HCS technologiques avancés. Parallèlement à cela, les fabricants sont engagés dans l'activité de développement pour lancer des systèmes HCS avancés, nouveaux et efficaces. Le développement croissant dans le domaine des techniques avancées devrait encore stimuler la croissance du marché. Cependant, des difficultés telles que les réglementations strictes pour la production et la commercialisation des produits HCS devraient freiner la croissance du marché.
Data Bridge Market Research analyse que le marché européen du dépistage à haut contenu devrait atteindre la valeur de 1 057 169,94 milliers USD d'ici 2030, à un TCAC de 6,8 % au cours de la période de prévision 2023-2030.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en milliers de dollars américains |
|
Segments couverts |
Type de produit (instruments, consommables, logiciels, services et accessoires), application (dépistage primaire et secondaire, identification et validation de cibles, études de toxicité, profilage de composés et autres applications), technologie ( microscopie , cytométrie de flux, immunohistochimie, matrice extracellulaire, ELISA, Western Blotting et autres), utilisateur final (sociétés pharmaceutiques et biotechnologiques, organismes de recherche sous contrat, laboratoires, instituts universitaires et gouvernementaux, autres), canal de distribution (appels d'offres directs, ventes au détail) |
|
Pays couverts |
Allemagne, France, Royaume-Uni, Italie, Espagne, Russie, Turquie, Belgique, Danemark, Pays-Bas, Suisse, Suède, Pologne, Norvège, Finlande et reste de l'Europe |
|
Acteurs du marché couverts |
BD, Merck KGaA, Corning Incorporated, Carl Zeiss AG, Sartorius AG, Zifo RnD Solutions, Axxam S.p.A., Molecular Devices, LLC. (Subsidiary of Danaher Corporation), Thermo Fisher Scientific Inc., PerkinElmer Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Yokogawa Electric Corporation, Sysmex Corporation, Genedata AG, Miltenyi Biotec, Aligned Genetics, Inc. and among others |
Europe High Content Screening Market Definition
High-Content Screening (HCS), also known as High-Content Analysis (HCA), is an approach to cell biology that combines automated imaging and quantitative data analysis in a high-throughput format suitable for large-scale applications such as drug discovery and systems biology.
This market refers to the sector of the life sciences industry that focuses on the use of advanced imaging and analysis techniques to study and analyze cellular processes and biological phenomena on a large scale. HCS involves the automated imaging and quantitative analysis of cells or organisms using technologies such as fluorescence microscopy, automated liquid handling, and sophisticated image analysis software.
Europe High Content Screening Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Driver
- Advancement in Imaging Technologies used for High Content Screening
Imaging technologies have been at the forefront of High-Content Screening (HCS), enabling researchers to visualize and analyze cellular processes with unprecedented detail and precision. In addition to high-resolution imaging, there have been significant improvements in imaging speed and throughput. HCS helps in the analysis of a large number of samples, often in high-throughput formats. Imaging technologies have evolved to provide faster acquisition times, enabling researchers to analyze large datasets in a shorter period. High-speed imaging techniques, such as spinning disk confocal microscopy and light-sheet microscopy, allow for rapid image acquisition without compromising image quality, facilitating efficient screening workflows and data analysis.
Over the years, significant advancements have been made in imaging modalities, microscopy techniques, and imaging analysis tools, transforming the landscape of HCS and driving its market expansion.
Opportunity
- Rising Integration with Artificial Intelligence and Machine Learning in Drug Discovery and Development
AI techniques, such as machine learning and deep learning, can analyze large volumes of data generated in drug discovery and development processes. By processing diverse datasets, including HTS data, chemical and biological databases, and clinical trial data, AI algorithms can identify patterns, relationships, and trends that may not be readily apparent to human researchers. This can help accelerate the identification of potential drug candidates and optimize the drug discovery process.
Data science and AI are becoming increasingly important in drug discovery and development. In addition to generating new therapeutics, AI speeds up the work of existing drug discovery and clinical teams, helping them to make informed and highly accurate research decisions.
Thus, the integration of AI in drug discovery and development has the potential to accelerate the process, improve success rates, and reduce costs, which is expected to create an opportunity for market growth.
Restraints/Challenges
- Complexity Associated with Cellular and Molecular Samples
Cellular and molecular samples are inherently complex, consisting of multiple cellular components, intricate signaling pathways, and dynamic molecular interactions. Analyzing such complexity requires advanced imaging techniques, specialized reagents, and sophisticated algorithms to accurately capture and interpret the data. The complexity associated with cellular and molecular samples presents a significant challenge, which is expected to restrain market growth.
- Lack of Skilled and Certified Professionals to Operate HCS
The lack of skilled professionals proficient in operating HCS systems can limit the adoption and utilization of these technologies. Organizations may hesitate to invest in HCS platforms if they do not have the necessary personnel to effectively operate and maintain the equipment.
HCS requires expertise in handling complex imaging systems, data analysis software, and assay optimization. Inexperienced operators may struggle to optimize protocols, leading to suboptimal performance and compromised results. Skilled professionals are crucial for obtaining reliable and high-quality data from HCS assays. Hence, the lack of skilled and certified professionals to operate HCS is expected to pose a challenge to market growth.
Recent Developments
- In January 2023, Axion BioSystems announced the addition of the Omni Pro 12 to the Omni live-cell imaging product family. The new platform, which features integrated robotics and multiple designs compatible with any standard incubator, offers enhanced flexibility and efficiency to scientists and drug developers conducting live-cell imaging experiments. This advancement in the imaging technique would help drug discovery be efficient by having live cell imaging experiments.
- In December 2019, Olympus announced the U.S. launch of the scanR HCS station, a cell imaging solution that utilizes Artificial Intelligence (AI) to enable next-generation biological research. It combines the modularity and flexibility of a microscope-based setup with the automation, speed, throughput, and reproducibility of an HCS station. Olympus’ self-learning microscopy technology reduces photo-bleaching and improves acquisition speed, measurement sensitivity, and accuracy, facilitating longer observations with reduced influence on cell viability.
Europe High Content Screening Market Scope
The Europe high content screening market is segmented into five notable segments based on product type, application, technology, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Product Type
- Instruments
- Consumables
- Software
- Services
- Accessories
On the basis of product type, the market is segmented into instruments, consumables, software, services, and accessories.
Application
- Primary and Secondary Screening
- Target Identification & Validation
- Toxicity Studies
- Compound Profiling
- Others
On the basis of application, the market is segmented into primary and secondary screening, target identification & validation, toxicity studies, compound profiling, and others.
Technology
- Microscopy
- Flow Cytometry
- Extracellular Matrix Based Scaffold
- Western Blotting
- ELISA
- Immunohistochemistry
- Others
On the basis of technology, the market is segmented into microscopy, flow cytometry, extracellular matrix based scaffold, western blotting, ELISA, immunohistochemistry, and others.
End User
- Pharmaceutical and Biotechnology Companies
- Academic and Government Institutes
- Contract Research Organizations
- Laboratories
- Others
On the basis of end user, the market is segmented into pharmaceutical and biotechnology companies, academic and government institutes, contract research organizations, laboratories and others.
Distribution Channel
- Direct Tenders
- Retail Sales
On the basis of distribution channel, the market is segmented into direct tenders and retail sales.
Europe High Content Screening Market Regional Analysis/Insights
The Europe high content screening market is categorized into five notable segments based on product type, application, technology, end user, and distribution channel.
The countries covered in this market report Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Denmark, Netherlands, Switzerland, Sweden, Poland, Norway, Finland and Rest of Europe.
Germany is expected to dominate Europe region due to the increasing investment in high content screening and increasing demand from emerging markets and expansion, which is expected to boost market growth.
La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché du dépistage à haut contenu en Europe
Le paysage concurrentiel du marché européen du criblage à haute teneur fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et l'ampleur du produit, la domination des applications, la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise vers le marché européen du criblage à haute teneur.
Français Certains des principaux acteurs du marché opérant sur le marché européen du criblage à haute teneur sont BD, Merck KGaA, Corning Incorporated, Carl Zeiss AG, Sartorius AG, Zifo RnD Solutions, Axxam SpA, Molecular Devices, LLC. (Filiale de Danaher Corporation), Thermo Fisher Scientific Inc., PerkinElmer Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Yokogawa Electric Corporation, Sysmex Corporation, Genedata AG, Miltenyi Biotec, Aligned Genetics, Inc. et entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE HIGH CONTENT SCREENING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 EUROPE HIGH CONTENT SCREENING MARKET: REGULATIONS
6 MARKET OVERVIEW, EUROPE HIGH CONTENT SCREENING MARKET
6.1 DRIVERS
6.1.1 ADVANCEMENT IN IMAGING TECHNOLOGIES USED FOR HIGH CONTENT SCREENING
6.1.2 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS
6.1.3 INCREASING RESEARCH ACTIVITIES ASSOCIATED WITH THE USAGE OF HIGH CONTENT SCREENING
6.1.4 INCREASING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES
6.2 RESTRAINTS
6.2.1 HIGH COST ASSOCIATED WITH INITIAL SETUP AND MAINTENANCE
6.2.2 COMPLEXITY ASSOCIATED WITH CELLULAR AND MOLECULAR SAMPLES
6.3 OPPORTUNITIES
6.3.1 GROWING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS (CROS) PROVIDING HCS SERVICES
6.3.2 RISING INTEGRATION WITH ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DRUG DISCOVERY AND DEVELOPMENT
6.3.3 INCREASING GOVERNMENT INITIATIVE AND FUNDING IN R&D
6.4 CHALLENGES
6.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS TO OPERATE HCS
6.4.2 DATA SECURITY AND DATA MANAGEMENT PROBLEMS IN HCS
7 EUROPE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 CELL IMAGING AND ANALYSIS SYSTEM
7.2.1.1 FIXED
7.2.1.2 MOBILE
7.2.2 HIGH-CONTENT AND SCREENING SYSTEM
7.2.2.1 FIXED
7.2.2.2 MOBILE
7.2.3 FLOW CYTOMETRY
7.2.4 INVITROGEN HCA ONSTAGE INCUBATOR
7.2.5 MICROPLATE MOVER
7.2.6 OTHERS
7.3 SOFTWARE
7.4 CONSUMABLES
7.4.1 REAGENTS & ASSAY KITS
7.4.2 MICROPLATES
7.4.3 OTHERS
7.5 ACCESSORIES
7.6 SERVICES
8 EUROPE HIGH CONTENT SCREENING MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 PRIMARY AND SECONDARY SCREENING
8.2.1 INSTRUMENTS
8.2.2 CONSUMABLES
8.2.3 ACCESSORIES
8.2.4 SERVICES
8.3 TARGET IDENTIFICATION AND VALIDATION
8.3.1 INSTRUMENTS
8.3.2 CONSUMABLES
8.3.3 ACCESSORIES
8.3.4 SERVICES
8.4 TOXICITY STUDIES
8.4.1 INSTRUMENTS
8.4.2 CONSUMABLES
8.4.3 ACCESSORIES
8.4.4 SERVICES
8.5 COMPOUND PROFILING
8.5.1 INSTRUMENTS
8.5.2 CONSUMABLES
8.5.3 ACCESSORIES
8.5.4 SERVICES
8.6 OTHER APPLICATIONS
9 EUROPE HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 MICROSCOPY
9.3 FLOW CYTOMETRY
9.4 IMMUNOHISTOCHEMISTRY
9.5 MASS SPECTROMETRY
9.6 ELISA
9.7 WESTERN BLOTTING
9.8 OTHERS
9.8.1 3D CELL CULTURE MODEL
9.8.1.1 STEROIDS
9.8.1.2 ORGANOIDS
9.8.1.3 TISSUE ON A CHIP
9.8.2 EXTRACELLULAR MATRIX BASED SCAFFOLD
9.8.3 SYNTHETIC HYDROGEL AND SCAFFOLD
10 EUROPE HIGH CONTENT SCREENING MARKET, BY END USER
10.1 OVERVIEW
10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
10.2.1 INSTRUMENTS
10.2.2 CONSUMABLES
10.2.3 ACCESSORIES
10.2.4 SERVICES
10.3 CONTRACT RESEARCH ORGANIZATIONS
10.3.1 INSTRUMENTS
10.3.2 CONSUMABLES
10.3.3 ACCESSORIES
10.3.4 SERVICES
10.4 LABORATORIES
10.4.1 INSTRUMENTS
10.4.2 CONSUMABLES
10.4.3 ACCESSORIES
10.4.4 SERVICES
10.5 ACADEMIC AND GOVERNMENT INSTITUTES
10.5.1 INSTRUMENTS
10.5.2 CONSUMABLES
10.5.3 ACCESSORIES
10.5.4 SERVICES
10.6 OTHERS
11 EUROPE HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDERS
11.3 RETAIL SALES
12 EUROPE HIGH CONTENT SCREENING MARKET, BY REGION
12.1 OVERVIEW
12.1.1 GERMANY
12.1.2 FRANCE
12.1.3 U.K.
12.1.4 ITALY
12.1.5 SPAIN
12.1.6 RUSSIA
12.1.7 TURKEY
12.1.8 BELGIUM
12.1.9 DENMARK
12.1.10 NETHERLANDS
12.1.11 SWITZERLAND
12.1.12 SWEDEN
12.1.13 POLAND
12.1.14 NORWAY
12.1.15 FINLAND
12.1.16 REST OF EUROPE
13 EUROPE HIGH CONTENT SCREENING MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 EUROPE CONTENT SCREENING MARKET, COMPANY PROFILES
14.1 THERMO FISHER SCIENTIFIC INC. (2022)
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 MOLECULAR DEVICES, LLC. (A SUBSIDIARY OF DANAHER CORPORATION)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.3 PERKINELMER INC. (2022)
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENTS
14.4 YOKOGAWA ELECTRIC CORPORATION (2022)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 RECENT DEVELOPMENT
14.5 BD
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENTS
14.6 MERCK KGAA
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 AGILENT TECHNOLOGIES, INC. (2022)
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 ALIGNED GENETICS, INC. (2022)
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 AXXAM S.P.A.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 BIO-RAD LABORATORIES, INC. (2022)
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 CARL ZEISS AG
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 CORNING INCORPORATED
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENT
14.13 GENEDATA AG
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MILTENYI BIOTEC
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 SARTORIUS AG
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.16 SYSMEX CORPORATION
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENT
14.17 ZIFO RND SOLUTIONS
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
TABLE 1 EUROPE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 2 EUROPE INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 3 EUROPE CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 4 EUROPE HIGH-CONTENT AND SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 5 EUROPE CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 6 EUROPE HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 7 EUROPE PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 8 EUROPE TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 9 EUROPE TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 10 EUROPE COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 11 EUROPE HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 12 EUROPE OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 13 EUROPE 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 14 EUROPE HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 15 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 16 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 17 EUROPE LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 18 EUROPE ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 19 EUROPE HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 20 EUROPE HIGH CONTENT SCREENING MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 21 GERMANY HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 22 GERMANY INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 23 GERMANY CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 24 GERMANY HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 25 GERMANY CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 26 GERMANY HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 27 GERMANY PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 28 GERMANY TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 29 GERMANY TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 30 GERMANY COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 31 GERMANY HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 32 GERMANY OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 33 GERMANY 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 34 GERMANY HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 35 GERMANY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 36 GERMANY CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 37 GERMANY LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 38 GERMANY ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 39 GERMANY HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 40 FRANCE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 41 FRANCE INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 42 FRANCE CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 43 FRANCE HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 44 FRANCE CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 45 FRANCE HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 46 FRANCE PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 47 FRANCE TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 48 FRANCE TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 FRANCE COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 FRANCE HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 51 FRANCE OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 52 FRANCE 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 53 FRANCE HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 54 FRANCE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 55 FRANCE CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 56 FRANCE LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 57 FRANCE ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 58 FRANCE HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 59 U.K. HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 U.K. INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 61 U.K. CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 U.K. HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 U.K. CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 64 U.K. HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 65 U.K. PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 66 U.K. TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 67 U.K. TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 68 U.K. COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 69 U.K. HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 70 U.K. OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 71 U.K. 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 72 U.K. HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 73 U.K. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 74 U.K. CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 75 U.K. LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 76 U.K. ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 77 U.K. HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 78 ITALY HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 79 ITALY INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 80 ITALY CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 81 ITALY HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 ITALY CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 83 ITALY HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 84 ITALY PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 85 ITALY TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 86 ITALY TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 87 ITALY COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 88 ITALY HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 89 ITALY OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 90 ITALY 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 91 ITALY HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 92 ITALY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 93 ITALY CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 94 ITALY LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 95 ITALY ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 96 ITALY HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 97 SPAIN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 98 SPAIN INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 99 SPAIN CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 100 SPAIN HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 101 SPAIN CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 102 SPAIN HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 103 SPAIN PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 104 SPAIN TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 105 SPAIN TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 106 SPAIN COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 107 SPAIN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 108 SPAIN OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 109 SPAIN 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 110 SPAIN HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 111 SPAIN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 112 SPAIN CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 113 SPAIN LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 114 SPAIN ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 115 SPAIN HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 116 RUSSIA HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 117 RUSSIA INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 118 RUSSIA CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 119 RUSSIA HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 120 RUSSIA CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 121 RUSSIA HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 122 RUSSIA PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 123 RUSSIA TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 124 RUSSIA TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 125 RUSSIA COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 126 RUSSIA HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 127 RUSSIA OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 128 RUSSIA 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 129 RUSSIA HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 130 RUSSIA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 131 RUSSIA CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 132 RUSSIA LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 133 RUSSIA ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 134 RUSSIA HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 135 TURKEY HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 136 TURKEY INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 137 TURKEY CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 138 TURKEY HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 139 TURKEY CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 140 TURKEY HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 141 TURKEY PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 142 TURKEY TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 143 TURKEY TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 144 TURKEY COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 145 TURKEY HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 146 TURKEY OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 147 TURKEY 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 148 TURKEY HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 149 TURKEY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 150 TURKEY CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 151 TURKEY LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 152 TURKEY ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 153 TURKEY HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 154 BELGIUM HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 155 BELGIUM INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 156 BELGIUM CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 BELGIUM HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 158 BELGIUM CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 159 BELGIUM HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 160 BELGIUM PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 161 BELGIUM TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 162 BELGIUM TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 163 BELGIUM COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 164 BELGIUM HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 165 BELGIUM OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 166 BELGIUM 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 167 BELGIUM HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 168 BELGIUM PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 169 BELGIUM CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 170 BELGIUM LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 171 BELGIUM ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 172 BELGIUM HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 173 DENMARK HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 174 DENMARK INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 175 DENMARK CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 176 DENMARK HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 177 DENMARK CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 178 DENMARK HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 179 DENMARK PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 180 DENMARK TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 181 DENMARK TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 182 DENMARK COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 183 DENMARK HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 184 DENMARK OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 185 DENMARK 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 186 DENMARK HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 187 DENMARK PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 188 DENMARK CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 189 DENMARK LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 190 DENMARK ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 191 DENMARK HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 192 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 193 NETHERLANDS INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 194 NETHERLANDS CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 195 NETHERLANDS HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 196 NETHERLANDS CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 197 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 198 NETHERLANDS PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 199 NETHERLANDS TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 200 NETHERLANDS TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 201 NETHERLANDS COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 202 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 203 NETHERLANDS OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 204 NETHERLANDS 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 205 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 206 NETHERLANDS PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 207 NETHERLANDS CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 208 NETHERLANDS LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 209 NETHERLANDS ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 210 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 211 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 212 SWITZERLAND INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 213 SWITZERLAND CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 214 SWITZERLAND HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 215 SWITZERLAND CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 216 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 217 SWITZERLAND PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 218 SWITZERLAND TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 219 SWITZERLAND TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 220 SWITZERLAND COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 221 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 222 SWITZERLAND OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 223 SWITZERLAND 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 224 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 225 SWITZERLAND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 226 SWITZERLAND CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 227 SWITZERLAND LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 228 SWITZERLAND ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 229 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 230 SWEDEN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 231 SWEDEN INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 232 SWEDEN CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 233 SWEDEN HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 234 SWEDEN CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 235 SWEDEN HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 236 SWEDEN PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 237 SWEDEN TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 238 SWEDEN TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 239 SWEDEN COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 240 SWEDEN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 241 SWEDEN OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 242 SWEDEN 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 243 SWEDEN HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 244 SWEDEN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 245 SWEDEN CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 246 SWEDEN LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 247 SWEDEN ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 248 SWEDEN HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 249 POLAND HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 250 POLAND INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 251 POLAND CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 252 POLAND HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 253 POLAND CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 254 POLAND HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 255 POLAND PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 256 POLAND TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 257 POLAND TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 258 POLAND COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 259 POLAND HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 260 POLAND OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 261 POLAND 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 262 POLAND HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 263 POLAND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 264 POLAND CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 265 POLAND LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 266 POLAND ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 267 POLAND HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 268 NORWAY HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 269 NORWAY INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 270 NORWAY CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 271 NORWAY HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 272 NORWAY CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 273 NORWAY HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 274 NORWAY PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 275 NORWAY TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 276 NORWAY TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 277 NORWAY COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 278 NORWAY HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 279 NORWAY OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 280 NORWAY 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 281 NORWAY HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 282 NORWAY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 283 NORWAY CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 284 NORWAY LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 285 NORWAY ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 286 NORWAY HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 287 FINLAND HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 288 FINLAND INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 289 FINLAND CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 290 FINLAND HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 291 FINLAND CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 292 FINLAND HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 293 FINLAND PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 294 FINLAND TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 295 FINLAND TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 296 FINLAND COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 297 FINLAND HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 298 FINLAND OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 299 FINLAND 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 300 FINLAND HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 301 FINLAND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 302 FINLAND CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 303 FINLAND LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 304 FINLAND ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 305 FINLAND HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 306 REST OF EUROPE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
Liste des figures
FIGURE 1 EUROPE HIGH CONTENT SCREENING MARKET: SEGMENTATION
FIGURE 2 EUROPE HIGH CONTENT SCREENING MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE HIGH CONTENT SCREENING MARKET: DROC ANALYSIS
FIGURE 4 EUROPE HIGH CONTENT SCREENING MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE HIGH CONTENT SCREENING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE HIGH CONTENT SCREENING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE HIGH CONTENT SCREENING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE HIGH CONTENT SCREENING MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE HIGH CONTENT SCREENING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE HIGH CONTENT SCREENING MARKET: SEGMENTATION
FIGURE 11 ADVANCEMENT IN IMAGING TECHNOLOGIES USED FOR HIGH-CONTENT SCREENING IS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE HIGH CONTENT SCREENING MARKET IN THE FORECAST PERIOD
FIGURE 12 THE PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE HIGH CONTENT SCREENING MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE HIGH CONTENT SCREENING MARKET
FIGURE 14 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 16 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 EUROPE HIGH CONTENT SCREENING MARKET: BY APPLICATION, 2022
FIGURE 19 EUROPE HIGH CONTENT SCREENING MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 20 EUROPE HIGH CONTENT SCREENING MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 21 EUROPE HIGH CONTENT SCREENING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 22 EUROPE HIGH CONTENT SCREENING MARKET: BY TECHNOLOGY, 2022
FIGURE 23 EUROPE HIGH CONTENT SCREENING MARKET: BY TECHNOLOGY, 2023-2030 (USD THOUSAND)
FIGURE 24 EUROPE HIGH CONTENT SCREENING MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 25 EUROPE HIGH CONTENT SCREENING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 26 EUROPE HIGH CONTENT SCREENING MARKET: BY END USER, 2022
FIGURE 27 EUROPE HIGH CONTENT SCREENING MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 28 EUROPE HIGH CONTENT SCREENING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 EUROPE HIGH CONTENT SCREENING MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 EUROPE HIGH CONTENT SCREENING MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 EUROPE HIGH CONTENT SCREENING MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 32 EUROPE HIGH CONTENT SCREENING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 EUROPE HIGH CONTENT SCREENING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 EUROPE HIGH CONTENT SCREENING MARKET: SNAPSHOT (2022)
FIGURE 35 EUROPE HIGH CONTENT SCREENING MARKET: BY COUNTRY (2022)
FIGURE 36 EUROPE HIGH CONTENT SCREENING MARKET: BY COUNTRY (2023 & 2030)
FIGURE 37 EUROPE HIGH CONTENT SCREENING MARKET: BY COUNTRY (2022 & 2030)
FIGURE 38 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 39 EUROPE HIGH CONTENT SCREENING MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
